### Learner Feedback Questions #308

1. In the U.S., which group accounts for 75 percent of all scleroderma cases?
   a. children ages 2-12
   b. men over 50
   c. women ages 40-55
   d. men and women in their 20s

2. How long does it usually take until a patient is definitively diagnosed with scleroderma?
   a. 3-6 months
   b. 6 months-1 year
   c. 1-3 years
   d. 3-5 years

3. Which of the following is does NOT define scleroderma?
   a. autoimmune disease
   b. hallmark is excessive collagen
   c. pathogenesis can involve numerous organs
   d. etiology has been clearly defined

4. Raynaud’s disease, a common symptom of scleroderma, is:
   a. tightness and thickness of the skin of the fingers
   b. coldness, numbness, cyanotic and hyperemic color changes of the hands, earlobes and toes
   c. digital ulcers, difficult to heal on the fingers and toes
   d. thinning of the skin of the fingers and toes, prone to tissue sloughing

5. A common pulmonary complication of scleroderma is:
   a. chronic bronchitis
   b. sarcoidosis
   c. tuberculosis
   d. alveolitis

6. Of the following organ systems, which is the least affected in patients with scleroderma?
   a. neurological
   b. musculoskeletal
   c. cardiac
   d. gastrointestinal

7. Renal involvement in scleroderma is no longer the most severe complication since the advent of:
   a. corticosteroids
   b. hemodialysis
   c. ACE inhibitors
   d. renal transplantation

8. The purpose of using calcium channel blockers in scleroderma treatment is to:
   a. open blood vessels in the skin and heart
   b. decrease the autoimmune response systematically
   c. slow pulmonary fibrosis in the lungs
   d. decrease bacterial overgrowth in the lower bowel

9. Patients with scleroderma often choose alternative treatments because:
   a. the cost of therapy is less
   b. there are too few rheumatologists in the U.S.
   c. newly diagnosed patients may have little information about the disease process
   d. some alternative meds show more promise than those prescribed

10. With treatment, the 5-year survival rate for scleroderma is over:
    a. 20 percent
    b. 40 percent
    c. 60 percent
    d. 80 percent

### Evaluation

1. I can define and discuss scleroderma in terms of its diagnosis, treatment, acuity and progression.
   a. strongly agree
   b. agree
   c. neutral
   d. disagree
   e. strongly disagree

2. I can discuss the pathogenesis of scleroderma.
   a. strongly agree
   b. agree
   c. neutral
   d. disagree
   e. strongly disagree

3. I can plan the nursing care for a patient with scleroderma according to the patient’s symptoms.
   a. strongly agree
   b. agree
   c. neutral
   d. disagree
   e. strongly disagree

4. The objectives relate to the overall goal of the article.
   a. strongly agree
   b. agree
   c. neutral
   d. disagree
   e. strongly disagree

5. The article is well-written and logically organized, and defines terms adequately.
   a. strongly agree
   b. agree
   c. neutral
   d. disagree
   e. strongly disagree

### Instructions

**Before April 4, 2014**, print this page, complete the multiple choice questions by circling the correct answer and mail or fax to: ADVANCE for Nurses, Learning Scope, 2900 Horizon Dr., King of Prussia, PA 19406; 610-278-1426.

**CUSTOMER INFORMATION**

For accuracy, please print clearly. (via)

| Name: |
| Street Address: |
| City: | State: | Zip: |
| Daytime Phone: |
| E-Mail Address: |

**PAYMENT $8**

Make check (any checks returned for non-sufficient funds will be assessed a $25 service fee) or money order payable to Merion Publications Learning Scope, 2900 Horizon Dr., King of Prussia, PA 19406, or pay by credit card:

| Name of Cardholder: |
| Credit Card No.: |
| Exp. Date: |

**THIS OFFERING EXPIRES IN 2 YEARS:**

**JUNE 8, 2011**

**4 APRIL 2014**

Keep **ADVANCE** Coming!

This may be only a trial copy or it may be time to renew. You won’t continue to receive **ADVANCE for Nurses** unless you contact us for your FREE subscription.

- YES! I am an RN, sign me up!

**Date:**
**Signature:**

- E-mail:

**JOB TITLE** that best describes your position *(fill in just one circle completely)*

- Director of Nursing (DON)
- Nursing Faculty
- Manager/Supervisor
- Private Practice
- Nurse Practitioner
- Senior Nursing Student
- Nursing Administrator
- Other:

**PRACTICE SETTING** that best describes your setting *(fill in just one circle completely)*

- Ambulatory
- Home Health
- Critical Care
- Hospice
- Chemical Dependency
- Infectious Control
- Critical Care
- Interventional
- Cardiac
- Dialysis
- IV Therapy
- Gastroenterology
- Dialysis
- Managerial/Administrative
- OB/GYN
- Education
- EMT
- Maternal/Child
- Emergency Department
- Geriatrics/LTC
- Med/Surg
- Gynecology
- Pediatrics
- Psychiatric
- No, I do not wish to receive a FREE subscription.

**Registration/Answer Form #308**

<table>
<thead>
<tr>
<th>LEARNER FEEDBACK QUESTIONS</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. A B C D</td>
</tr>
<tr>
<td>2. A B C D</td>
</tr>
<tr>
<td>3. A B C D</td>
</tr>
<tr>
<td>4. A B C D</td>
</tr>
<tr>
<td>5. A B C D</td>
</tr>
<tr>
<td>6. A B C D</td>
</tr>
<tr>
<td>7. A B C D</td>
</tr>
<tr>
<td>8. A B C D</td>
</tr>
<tr>
<td>9. A B C D</td>
</tr>
<tr>
<td>10. A B C D</td>
</tr>
</tbody>
</table>

**Reg/Ans Form #308**

**LEARNER FEEDBACK QUESTIONS #308**

**Evaluation**

| I can define and discuss scleroderma in terms of its diagnosis, treatment, acuity and progression. |
| a. strongly agree |
| b. agree |
| c. neutral |
| d. disagree |
| e. strongly disagree |

| I can discuss the pathogenesis of scleroderma. |
| a. strongly agree |
| b. agree |
| c. neutral |
| d. disagree |
| e. strongly disagree |

| I can plan the nursing care for a patient with scleroderma according to the patient’s symptoms. |
| a. strongly agree |
| b. agree |
| c. neutral |
| d. disagree |
| e. strongly disagree |

| The objectives relate to the overall goal of the article. |
| a. strongly agree |
| b. agree |
| c. neutral |
| d. disagree |
| e. strongly disagree |

| The article is well-written and logically organized, and defines terms adequately. |
| a. strongly agree |
| b. agree |
| c. neutral |
| d. disagree |
| e. strongly disagree |